Cnossen MH[au] - Search Results

Year	Number of Results
1994	1
1997	3
1998	3
2001	1
2009	2
2010	2
2011	1
2012	3
2013	3
2014	8
2015	10
2016	16
2017	9
2018	17
2019	11
2020	14
2021	25
2022	4

1

[Haemophilia].

Loomans JI, Lock J, Peters M, Leebeek FW, Cnossen MH, Fijnvandraat K. Loomans JI, et al. Among authors: cnossen mh. Ned Tijdschr Geneeskd. 2014;158:A7357. Ned Tijdschr Geneeskd. 2014. PMID: 25351381 Review. Dutch.

2

Defining patient value in haemophilia care.

van Balen EC, Gouw SC, Hazelzet JA, van der Bom JG, Cnossen MH. van Balen EC, et al. Among authors: cnossen mh. Haemophilia. 2018 Jul;24(4):516-518. doi: 10.1111/hae.13550. Haemophilia. 2018. PMID: 30141573 No abstract available.

3

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA. Preijers T, et al. Among authors: cnossen mh. Clin Pharmacokinet. 2021 Jan;60(1):1-16. doi: 10.1007/s40262-020-00936-5. Clin Pharmacokinet. 2021. PMID: 32936401 Free PMC article. Review.

4

Diagnosis and management of haemophilia.

Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Fijnvandraat K, et al. Among authors: cnossen mh. BMJ. 2012 May 2;344:e2707. doi: 10.1136/bmj.e2707. BMJ. 2012. PMID: 22551712 Free article. Review. No abstract available.

5

Patient-reported outcomes in autosomal inherited bleeding disorders: A systematic literature review.

van Hoorn ES, Houwing ME, Al Arashi W, Leebeek FWG, Hazelzet JA, Gouw SC, Schutgens REG, Schols SEM, Lingsma HF, Cnossen MH; SYMPHONY consortium. van Hoorn ES, et al. Among authors: cnossen mh. Haemophilia. 2022 Jan 18. doi: 10.1111/hae.14492. Online ahead of print. Haemophilia. 2022. PMID: 35040234 Review.

6

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.

Goedhart TMHJ, Bukkems LH, Zwaan CM, Mathôt RAA, Cnossen MH; OPTI-CLOT study group and SYMPHONY consortium. Goedhart TMHJ, et al. Among authors: cnossen mh. Blood Adv. 2021 Oct 26;5(20):4314-4325. doi: 10.1182/bloodadvances.2021005096. Blood Adv. 2021. PMID: 34496017 Free article. Review.

7

Sickle cell disease: Clinical presentation and management of a global health challenge.

Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Schols EM, Philipsen JNJ, Tamminga RYJ, van Draat KF, Nur E, Cnossen MH; SCORE Consortium. Houwing ME, et al. Among authors: cnossen mh. Blood Rev. 2019 Sep;37:100580. doi: 10.1016/j.blre.2019.05.004. Epub 2019 May 20. Blood Rev. 2019. PMID: 31128863 Review.

8

Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?

Hazendonk HCAM, van Moort I, Mathôt RAA, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH; OPTI-CLOT study group. Hazendonk HCAM, et al. Among authors: cnossen mh. Blood Rev. 2018 Jul;32(4):265-271. doi: 10.1016/j.blre.2018.01.001. Epub 2018 Jan 31. Blood Rev. 2018. PMID: 29426727 Free article. Review.

9

Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA. Preijers T, et al. Among authors: cnossen mh. Ther Drug Monit. 2019 Apr;41(2):192-212. doi: 10.1097/FTD.0000000000000625. Ther Drug Monit. 2019. PMID: 30883513 Review.

10

[Von Willebrand disease in the Netherlands: the WiN study].

Sanders YV, de Wee EM, Meijer K, Eikenboom J, van der Bom JG, Fijnvandraat CJ, Laros-van Gorkom BA, Cnossen MH, Mauser-Bunschoten EP, Leebeek FW. Sanders YV, et al. Among authors: cnossen mh. Ned Tijdschr Geneeskd. 2014;158:A6518. Ned Tijdschr Geneeskd. 2014. PMID: 24800796 Review. Dutch.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results